India's generic semaglutide market settles into a price war six months on

India's patent on semaglutide, the drug sold abroad as Ozempic and Wegovy, lapsed on March 20, 2026. The very day it expired, more than a dozen Indian drugmakers launched their own versions of the injectable medicine, touching off a price war that has reshaped the country's diabetes and weight-loss drug market ^[1].

Dr. Reddy's Laboratories entered with a product called Obeda, priced at about 4,200 rupees a month, and received expedited approval from India's Drugs Controller General on launch day ^[1]. The pen comes in 2 mg and 4 mg strengths for once-weekly injection, and the company has emphasized cold-chain handling of the product ^[1]. But Obeda's price sits well above rivals. Sun Pharmaceutical Industries, Lupin, and Natco Pharma were among the companies that launched competing generics the same day, and some versions in vial form have been reported as low as 1,290 rupees a month ^[1]. That is a steep gap from the roughly 8,800 to 10,850 rupees a month that the original branded product had cost in India before generic competition began ^[1].

India's regulators and industry watchers say the field could get even more crowded. Reports at the time of launch pointed to more than 40 manufacturers potentially bringing out versions under as many as 50 different brand names, raising the prospect of further price cuts as companies compete for market share ^[1]. Dr. Reddy's has said its ambitions extend beyond India: chief executive Erez Israeli has described plans for global expansion of generic semaglutide under a single quality standard, and M V Ramana, who leads the company's branded markets business, has said the goal is to widen access to the therapy ^[1].

The scale of the diabetes population helps explain why so many companies moved quickly. India has more than 101 million adults with diabetes, one of the largest such populations in the world, and semaglutide-class drugs are used to help regulate blood sugar and appetite ^[1]. Analysts have projected India's GLP-1 receptor agonist market could grow to roughly $347.5 million by 2035, even as low prices squeeze margins for individual manufacturers ^[1].

Why it matters for patients

For patients outside India, the immediate relevance is limited: none of these generic products are approved or sold in the United States, where semaglutide remains under patent and is marketed as Ozempic, Wegovy, and Rybelsus. But the India launch is being watched closely because it shows what happens to prices once a semaglutide patent lapses and multiple manufacturers compete head-to-head. In India, that competition pushed monthly costs down from thousands of rupees to, in some cases, close to a tenth of the original price within days of generic entry ^[1].

The crowded field also raises questions about consistency across brands. With dozens of companies making the same molecule under different names, there could be variation in packaging, injection devices, or supply reliability, though no specific quality problems have been reported in connection with the launches described here ^[1]. Analyst views on how individual manufacturers will fare are mixed, with ratings on Dr. Reddy's shares ranging from "hold" to "strong buy" as investors weigh the tradeoff between higher volume and thinner margins ^[1].

What happens next

Dr. Reddy's has said it is pursuing broader international rollout of its generic semaglutide, framing the Indian launch as an early test of a strategy it hopes to repeat elsewhere ^[1]. Details on specific timelines, additional country approvals, or how U.S. patent expiration might eventually affect pricing here are not established in the available reporting and remain to be seen.